



## Clinical trial results:

### An Exploratory Phase 2, Randomised, Double-blind, Placebo-controlled, and Open-label Active Comparator Study to Evaluate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects with Type 2 Diabetes Mellitus

#### Summary

EudraCT number	2017-005081-22
Trial protocol	SE GB
Global end of trial date	26 August 2021

#### Results information

Result version number	v3 (current)
This version publication date	26 February 2025
First version publication date	27 April 2022
Version creation reason	

#### Trial information

##### Trial identification

Sponsor protocol code	D5670C00022
-----------------------	-------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	AstraZeneca Clinical Study Information Center
Sponsor organisation address	One Medimmune Way, Gaithersburg, United States, 20878
Public contact	Medical Monitor, AstraZeneca Clinical Study Information Center, +1 877-240-9479, information.center@astrazeneca.com
Scientific contact	Medical Monitor, AstraZeneca Clinical Study Information Center, +1 877-240-9479, information.center@astrazeneca.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	16 September 2021
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	26 August 2021
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To assess the effect of MEDI0382 on hepatic glycogen levels versus placebo after 28 days (Part A) and 35 days (Part B) of treatment

Protection of trial subjects:

The conduct of this clinical study met all local legal and regulatory requirements. The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki, and that are consistent with GCP and the applicable regulatory requirement(s).

Background therapy:

MEDI0382 is a synthetic peptide with both glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist activity which is under development for the treatment of T2DM and non-alcoholic steatohepatitis (NASH). GLP-1 receptor agonists are established treatments for T2DM that improve glycaemic control, delay gastric emptying, and depress appetite leading to modest, but often non-sustained weight loss (typically 3% versus baseline at one year). Glucagon has similar effects to GLP-1 on gastric emptying and appetite, and has also been shown to promote increased energy expenditure (Lynch et al, 2014; Habegger et al, 2013). Oxyntomodulin, a naturally occurring peptide with GLP-1 and glucagon receptor co-agonist activity, has been shown to promote weight loss through effects on appetite and energy expenditure (Wynne et al, 2006) and co-infusion of GLP-1 and glucagon has synergistic effects on reducing food intake and promoting weight loss in human subjects (Bagger et al, 2015).

Evidence for comparator:

Liraglutide is an analog with 97% homology to human glucagon-like peptide (GLP-1) and acts as a GLP-1 receptor agonist. Several large, randomized, multicenter phase 3 trials evaluated the efficacy and safety of liraglutide by comparing monotherapy and combination therapy with other antidiabetic medications in adult patients with type 2 diabetes. The Liraglutide Effect and Action in Diabetes (LEAD) program demonstrated that liraglutide, when used alone or in combination with other antidiabetic medications, effectively controls hyperglycemia (glycosylated hemoglobin [A1C] reductions up to 1.6%) and assists patients in meeting established glycemic targets. Compared with certain other classes of antidiabetic agents, liraglutide is associated with a lower risk of hypoglycemia. Liraglutide has also been associated with weight loss (1.8 to 3.4 kg) and improved patient satisfaction and health-related quality of life.

Actual start date of recruitment	31 May 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Netherlands: 16
Country: Number of subjects enrolled	Sweden: 35
Worldwide total number of subjects	51
EEA total number of subjects	51

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	21
From 65 to 84 years	30
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

A total of 51 participants (total for Part A [21 participants] and B [30 participants]) participated in the study from 31 May 2018 (date first participant enrolled) to 14 April 2021 (date of last participant last visit) at one site in Sweden for Part A, and 2 sites (one in Sweden and one in the Netherlands) for Part B.

### Pre-assignment

Screening details:

A total of 95 participants consented to participate in the study (36 from Part A and 59 from Part B) from one site in Sweden for Part A, and 2 sites (one in Sweden and one in the Netherlands) for Part B. Of these, 15 participants from Part A and 29 participants from Part B were considered screen failures.

### Pre-assignment period milestones

Number of subjects started	51
Number of subjects completed	51

### Period 1

Period 1 title	Baseline period
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Carer, Data analyst, Assessor

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	MEDI0382 (Part A)

Arm description: -

Arm type	Experimental
Investigational medicinal product name	Cotadutide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

MEDI0382 100 µg for 7 days, followed by 200 µg for 7 days, followed by 300 µg for 14 days once daily in the morning via SC injection as

<b>Arm title</b>	Placebo (Part A)
------------------	------------------

Arm description: -

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Placebo for 28 days

<b>Arm title</b>	Liraglutide (Part B)
------------------	----------------------

Arm description: -	
Arm type	Active comparator
Investigational medicinal product name	Victoza
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use
Dosage and administration details:	
Open label liraglutide 0.6 mg for 7 days, followed by 1.2 mg for 7 days, followed by 1.8 mg for 21 days	
<b>Arm title</b>	MEDI0382 (Part B)
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	Cotadutide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use
Dosage and administration details:	
MEDI0382 50 µg for 7 days, followed by 100 µg for 7 days, followed by 200 µg for 7 days, followed by 300 µg for 14 days	
<b>Arm title</b>	Placebo (Part B)
Arm description: -	
Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use
Dosage and administration details:	
Placebo for 35 days	

<b>Number of subjects in period 1</b>	MEDI0382 (Part A)	Placebo (Part A)	Liraglutide (Part B)
Started	12	9	10
Completed	12	9	10

<b>Number of subjects in period 1</b>	MEDI0382 (Part B)	Placebo (Part B)
Started	9	11
Completed	9	11

**Period 2**

Period 2 title	Treatment Period
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Carer, Data analyst, Assessor

**Arms**

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	MEDI0382 (Part A)
------------------	-------------------

Arm description: -

Arm type	Experimental
Investigational medicinal product name	Cotadutide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

MEDI0382 100 µg for 7 days, followed by 200 µg for 7 days, followed by 300 µg for 14 days once daily in the morning via SC injection as

<b>Arm title</b>	Placebo (Part A)
------------------	------------------

Arm description: -

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Placebo for 28 days

<b>Arm title</b>	Liraglutide (Part B)
------------------	----------------------

Arm description: -

Arm type	Active comparator
Investigational medicinal product name	Victoza
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Open label liraglutide 0.6 mg for 7 days, followed by 1.2 mg for 7 days, followed by 1.8 mg for 21 days

<b>Arm title</b>	MEDI0382 (Part B)
------------------	-------------------

Arm description: -

Arm type	Experimental
Investigational medicinal product name	Cotadutide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

MEDI0382 50 µg for 7 days, followed by 100 µg for 7 days, followed by 200 µg for 7 days, followed by 300 µg for 14 days

<b>Arm title</b>	Placebo (Part B)
Arm description: -	
Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Placebo for 35 days

<b>Number of subjects in period 2</b>	MEDI0382 (Part A)	Placebo (Part A)	Liraglutide (Part B)
Started	12	9	10
Completed	12	9	10

<b>Number of subjects in period 2</b>	MEDI0382 (Part B)	Placebo (Part B)
Started	9	11
Completed	9	11

## Baseline characteristics

### Reporting groups

Reporting group title	MEDI0382 (Part A)
Reporting group description: -	
Reporting group title	Placebo (Part A)
Reporting group description: -	
Reporting group title	Liraglutide (Part B)
Reporting group description: -	
Reporting group title	MEDI0382 (Part B)
Reporting group description: -	
Reporting group title	Placebo (Part B)
Reporting group description: -	

Reporting group values	MEDI0382 (Part A)	Placebo (Part A)	Liraglutide (Part B)
Number of subjects	12	9	10
Age Categorical Units: Subjects			
aged $\geq$ 18 years	12	9	10
Gender Categorical Units: Subjects			
Female	5	3	4
Male	7	6	6

Reporting group values	MEDI0382 (Part B)	Placebo (Part B)	Total
Number of subjects	9	11	51
Age Categorical Units: Subjects			
aged $\geq$ 18 years	9	11	51
Gender Categorical Units: Subjects			
Female	3	2	17
Male	6	9	34

### Subject analysis sets

Subject analysis set title	As-treated population
Subject analysis set type	Safety analysis
Subject analysis set description: Participants who received any study IP were included in the as-treated population and participants were analysed according to the treatment they actually received.	
Subject analysis set title	Intent-to-treat population
Subject analysis set type	Intention-to-treat
Subject analysis set description: Participants who received any study IP were included in the ITT population and participants were analysed according to their randomised treatment group.	



<b>Reporting group values</b>	As-treated population	Intent-to-treat population	
Number of subjects	51	51	
Age Categorical Units: Subjects			
aged ≥ 18 years	51	51	
Gender Categorical Units: Subjects			
Female	17	17	
Male	34	34	

## End points

### End points reporting groups

Reporting group title	MEDI0382 (Part A)
Reporting group description: -	
Reporting group title	Placebo (Part A)
Reporting group description: -	
Reporting group title	Liraglutide (Part B)
Reporting group description: -	
Reporting group title	MEDI0382 (Part B)
Reporting group description: -	
Reporting group title	Placebo (Part B)
Reporting group description: -	
Reporting group title	MEDI0382 (Part A)
Reporting group description: -	
Reporting group title	Placebo (Part A)
Reporting group description: -	
Reporting group title	Liraglutide (Part B)
Reporting group description: -	
Reporting group title	MEDI0382 (Part B)
Reporting group description: -	
Reporting group title	Placebo (Part B)
Reporting group description: -	
Subject analysis set title	As-treated population
Subject analysis set type	Safety analysis
Subject analysis set description: Participants who received any study IP were included in the as-treated population and participants were analysed according to the treatment they actually received.	
Subject analysis set title	Intent-to-treat population
Subject analysis set type	Intention-to-treat
Subject analysis set description: Participants who received any study IP were included in the ITT population and participants were analysed according to their randomised treatment group.	

### **Primary: Change in hepatic glycogen concentration adjusted for liver volume as measured by MRS at T = 4 hours post standardised morning meal from baseline (Day -1) to the end of 28 days of treatment (Part A only)**

End point title	Change in hepatic glycogen concentration adjusted for liver volume as measured by MRS at T = 4 hours post standardised morning meal from baseline (Day -1) to the end of 28 days of treatment (Part A only)
End point description: To assess the effect of MEDI0382 on hepatic glycogen levels postprandially versus placebo after 28 days of treatment	
End point type	Primary
End point timeframe: from baseline (Day -1) to the end of 28 days of treatment (Part A only)	

End point values	MEDI0382 (Part A)	Placebo (Part A)	Intent-to-treat population	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	12	9	21 <sup>[1]</sup>	
Units: mmol/L				
least squares mean (confidence interval 90%)				
Change from baseline	-100.2 (-150.2 to -50.1)	5.5 (-47.2 to 58.3)	-105.7 (-178.8 to -32.6)	

Notes:

[1] - Part A Only MEDI0382 (Part A) vs. Placebo (Part A)

## Statistical analyses

<b>Statistical analysis title</b>	Primary Analysis (Part A)
Statistical analysis description:	
To assess the effect of cotadutide on hepatic glycogen levels versus placebo after 28 days (Part A)	
Comparison groups	MEDI0382 (Part A) v Placebo (Part A)
Number of subjects included in analysis	21
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.023
Method	ANCOVA
Parameter estimate	Least square mean difference
Point estimate	-105.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-178.8
upper limit	-32.6

## Primary: Percentage change in fasting hepatic glycogen concentration adjusted for liver volume as measured by MRS at T = 24 hours post standardised morning meal from baseline (Day 1) to the end of 35 days of treatment (Day 36) (Part B)

End point title	Percentage change in fasting hepatic glycogen concentration adjusted for liver volume as measured by MRS at T = 24 hours post standardised morning meal from baseline (Day 1) to the end of 35 days of treatment (Day 36) (Part B)
End point description:	
End point type	Primary
End point timeframe:	
from baseline (Day 1) to the end of 35 days of treatment (Day 36) (Part B)	

End point values	MEDI0382 (Part B)	Placebo (Part B)	Intent-to-treat population	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	9	11	20 <sup>[2]</sup>	
Units: percent change from baseline				
least squares mean (confidence interval 90%)	-27.02 (-38.04 to -16.01)	-1.15 (-11.09 to 8.79)	-25.87 (-40.88 to -10.86)	

Notes:

[2] - Part B Only MEDI0382 (Part B) vs. Placebo (Part B)

## Statistical analyses

Statistical analysis title	Primary Analysis Part B
Statistical analysis description: To assess the effect of cotadutide on hepatic glycogen levels versus placebo after 35 days (Part B) of treatment	
Comparison groups	MEDI0382 (Part B) v Placebo (Part B) v Intent-to-treat population
Number of subjects included in analysis	40
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.008
Method	ANCOVA
Parameter estimate	Least square mean difference
Point estimate	-25.87
Confidence interval	
level	90 %
sides	2-sided
lower limit	-40.88
upper limit	-10.86

## Secondary: Percentage change in fasting hepatic glycogen concentration adjusted for liver volume as measured by MRS at T = 24 hours post standardised morning meal from baseline (Day 1) to the end of 35 days of treatment (Day 36, Part B only)

End point title	Percentage change in fasting hepatic glycogen concentration adjusted for liver volume as measured by MRS at T = 24 hours post standardised morning meal from baseline (Day 1) to the end of 35 days of treatment (Day 36, Part B only)
End point description: To assess the effect of MEDI0382 on hepatic glycogen levels versus liraglutide after 35 days of treatment (Part B only)	
End point type	Secondary
End point timeframe: From baseline (Day -1) to Day 35	

End point values	Liraglutide (Part B)	MEDI0382 (Part B)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	10	9		
Units: Percentage change from baseline				
least squares mean (confidence interval 90%)	-5.33 (-13.97 to 3.32)	-27.31 (-36.42 to -18.20)		

### Statistical analyses

Statistical analysis title	Comparing groups: MEDI0382 vs Liraglutide
Comparison groups	Liraglutide (Part B) v MEDI0382 (Part B)
Number of subjects included in analysis	19
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.008
Method	ANCOVA
Parameter estimate	Least Square Mean difference
Point estimate	-21.99
Confidence interval	
level	90 %
sides	2-sided
lower limit	-34.55
upper limit	-9.43

### Secondary: Change of hepatic fat fraction from baseline as measured by magnetic resonance imaging (Day -1) to the end of 35 days of treatment (Part B only)

End point title	Change of hepatic fat fraction from baseline as measured by magnetic resonance imaging (Day -1) to the end of 35 days of treatment (Part B only)
End point description:	
To assess the effect of cotadutide on hepatic fat fraction versus placebo after 35 days of treatment (Part B only)	
End point type	Secondary
End point timeframe:	
Day -1 to Day 36	

End point values	Liraglutide (Part B)	MEDI0382 (Part B)	Placebo (Part B)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	10	9	11	
Units: Percent				
least squares mean (confidence interval 90%)	-15.40 (-21.09 to -9.72)	-26.26 (-51.13 to -1.39)	8.79 (-10.46 to 28.05)	

## Statistical analyses

<b>Statistical analysis title</b>	Comparing groups: MEDI0382 vs Liraglutide
Comparison groups	Liraglutide (Part B) v MEDI0382 (Part B)
Number of subjects included in analysis	19
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.03
Method	ANCOVA
Parameter estimate	Least Square Mean difference
Point estimate	-11.72
Confidence interval	
level	90 %
sides	2-sided
lower limit	-20.13
upper limit	-3.3

<b>Statistical analysis title</b>	Comparing groups: MEDI0382 vs Placebo
Comparison groups	MEDI0382 (Part B) v Placebo (Part B)
Number of subjects included in analysis	20
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.07
Method	ANCOVA
Parameter estimate	Least Square Mean difference
Point estimate	-35.06
Confidence interval	
level	90 %
sides	2-sided
lower limit	-66.54
upper limit	-3.58

## Secondary: Development of Anti-drug antibody/antibodies (ADA)

End point title	Development of Anti-drug antibody/antibodies (ADA)
End point description: To characterise the immunogenicity profile of cotadutide titrated up to a dose level of 300 µg	
End point type	Secondary

End point timeframe:

Baseline to (Follow-up Period) 28 days post last dose + (3-month poststudy)

End point values	MEDI0382 (Part A)	Placebo (Part A)	Liraglutide (Part B)	MEDI0382 (Part B)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	9	10	9
Units: Participants				
Baseline ADA result	0	0	0	0
ADA result for Day 28 (Part A) and Day 35 (Part B)	1	0	0	3
Follow-up ADA result	0	0	0	3
Post Study ADA result	0	0	0	1

End point values	Placebo (Part B)			
Subject group type	Reporting group			
Number of subjects analysed	11			
Units: Participants				
Baseline ADA result	0			
ADA result for Day 28 (Part A) and Day 35 (Part B)	0			
Follow-up ADA result	0			
Post Study ADA result	0			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Measures of safety and tolerability of daily SC doses of MEDI0382 titrated up to a dose level of 300µg (Parts A and B) by assessment of Number of Participants with Treatment Emergent Adverse Events (TEAEs) as assessed by CTCAE V4.0

End point title	Measures of safety and tolerability of daily SC doses of MEDI0382 titrated up to a dose level of 300µg (Parts A and B) by assessment of Number of Participants with Treatment Emergent Adverse Events (TEAEs) as assessed by CTCAE V4.0
-----------------	---

End point description:

Safety and tolerability of daily SC doses of MEDI0382 by assessment of the following using CTCAE V4.0: The number of Treatment Emergent Adverse events (TEAEs)

End point type	Secondary
----------------	-----------

End point timeframe:

Post dosing (Day 1) to final follow-up (28 Days post last dose)

End point values	MEDI0382 (Part A)	Placebo (Part A)	Liraglutide (Part B)	MEDI0382 (Part B)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	9	10	9
Units: participants				
At least one event	11	7	8	7
At least one IP related event	7	5	7	7

End point values	Placebo (Part B)			
Subject group type	Reporting group			
Number of subjects analysed	11			
Units: participants				
At least one event	6			
At least one IP related event	3			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Measures of safety and tolerability of daily SC doses of MEDI0382 titrated up to a dose level of 300µg (Parts A and B) by assessment of Number of Participants with Treatment Emergent Serious Adverse Events (TESAEs) as assessed by CTCAE V4.0

End point title	Measures of safety and tolerability of daily SC doses of MEDI0382 titrated up to a dose level of 300µg (Parts A and B) by assessment of Number of Participants with Treatment Emergent Serious Adverse Events (TESAEs) as assessed by CTCAE V4.0
-----------------	--

End point description:

Safety and tolerability of daily SC doses of MEDI0382 by assessment of the following using CTCAE V4.0: The number of Treatment-Emergent Serious Adverse Events (TESAEs)

End point type	Secondary
----------------	-----------

End point timeframe:

Post dosing (Day 1) to final follow-up (28 Days post last dose)

End point values	MEDI0382 (Part A)	Placebo (Part A)	Liraglutide (Part B)	MEDI0382 (Part B)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	9	10	9
Units: Participants				
Treatment Emergent Serious Adverse Events (TESAEs)	0	0	0	0



<b>End point values</b>	Placebo (Part B)			
Subject group type	Reporting group			
Number of subjects analysed	11			
Units: Participants				
Treatment Emergent Serious Adverse Events(TESAEs)	0			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Measures of safety and tolerability of daily SC doses of MEDI0382 titrated up to a dose level of 300µg (Parts A and B) by assessment of changes in heart rate and blood pressure (BP)

End point title	Measures of safety and tolerability of daily SC doses of MEDI0382 titrated up to a dose level of 300µg (Parts A and B) by assessment of changes in heart rate and blood pressure (BP)
End point description:	
Number of subjects with clinically significant changes in heart rate (BPM) or systolic and diastolic blood pressure (mmHg)	
End point type	Secondary
End point timeframe:	
Post dosing (Day 1) to final follow-up (28 Days post last dose)	

<b>End point values</b>	MEDI0382 (Part A)	Placebo (Part A)	Liraglutide (Part B)	MEDI0382 (Part B)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	9	10	9
Units: Participants				
clinically significant changes in heartrate or BP	0	0	0	0

<b>End point values</b>	Placebo (Part B)			
Subject group type	Reporting group			
Number of subjects analysed	11			
Units: Participants				
clinically significant changes in heartrate or BP	0			

## Statistical analyses

No statistical analyses for this end point

**Secondary: Measures of safety and tolerability of daily SC doses of MEDI0382 titrated up to a dose level of 300µg (Parts A and B) by assessment of changes in ECG**

End point title	Measures of safety and tolerability of daily SC doses of MEDI0382 titrated up to a dose level of 300µg (Parts A and B) by assessment of changes in ECG
-----------------	--

End point description:

Number of subjects with an ECG determined to be abnormal and clinically significant

End point type	Secondary
----------------	-----------

End point timeframe:

Post dosing (Day 1) to final follow-up (28 Days post last dose)

End point values	MEDI0382 (Part A)	Placebo (Part A)	Liraglutide (Part B)	MEDI0382 (Part B)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	9	10	9
Units: participants				
ECG deemed abnormal and clinically significant	0	0	0	0

End point values	Placebo (Part B)			
Subject group type	Reporting group			
Number of subjects analysed	11			
Units: participants				
ECG deemed abnormal and clinically significant	0			

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Measures of safety and tolerability of daily SC doses of MEDI0382 titrated up to a dose level of 300µg (Parts A and B) by assessment of changes in haematology (Haem) and clinical (Clin) chemistry (Chem) parameters (Paras)**

End point title	Measures of safety and tolerability of daily SC doses of MEDI0382 titrated up to a dose level of 300µg (Parts A and B) by assessment of changes in haematology (Haem) and clinical (Clin) chemistry (Chem) parameters (Paras)
-----------------	---

End point description:

Number of subjects with clinically significant (sig) changes in haematology and or clinical chemistry parameters

End point type	Secondary
----------------	-----------

End point timeframe:

Post dosing (Day 1) to final follow-up (28 Days post last dose)

<b>End point values</b>	MEDI0382 (Part A)	Placebo (Part A)	Liraglutide (Part B)	MEDI0382 (Part B)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	9	10	9
Units: Participants				
clin sig changes in haem or clin chem paras	0	0	0	0

<b>End point values</b>	Placebo (Part B)			
Subject group type	Reporting group			
Number of subjects analysed	11			
Units: Participants				
clin sig changes in haem or clin chem paras	0			

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Post dosing (Day 1) to final follow-up (28 Days post last dose)

Adverse event reporting additional description:

Adverse events were coded with MedDRA version 21.0 or higher. Analysis of AEs included the type, incidence, severity and relationship to study IP summarised by MedDRA SOC and PT by study part treatment group as well as for combined study parts.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	21
--------------------	----

### Reporting groups

Reporting group title	MEDI0382 (Part A)
-----------------------	-------------------

Reporting group description: -

Reporting group title	Placebo (Part B)
-----------------------	------------------

Reporting group description: -

Reporting group title	MEDI0382 (Part B)
-----------------------	-------------------

Reporting group description: -

Reporting group title	Placebo (Part A)
-----------------------	------------------

Reporting group description: -

Reporting group title	Liraglutide (Part B)
-----------------------	----------------------

Reporting group description: -

Serious adverse events	MEDI0382 (Part A)	Placebo (Part B)	MEDI0382 (Part B)
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

Serious adverse events	Placebo (Part A)	Liraglutide (Part B)	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	MEDI0382 (Part A)	Placebo (Part B)	MEDI0382 (Part B)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	11 / 12 (91.67%)	6 / 11 (54.55%)	7 / 9 (77.78%)
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Chills			
subjects affected / exposed	2 / 12 (16.67%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	4	0	0
Fatigue			
subjects affected / exposed	6 / 12 (50.00%)	0 / 11 (0.00%)	3 / 9 (33.33%)
occurrences (all)	7	0	3
Early satiety			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Feeling cold			
subjects affected / exposed	1 / 12 (8.33%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Injection site erythema			
subjects affected / exposed	1 / 12 (8.33%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Injection site haematoma			
subjects affected / exposed	1 / 12 (8.33%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Injection site rash			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Malaise			
subjects affected / exposed	2 / 12 (16.67%)	0 / 11 (0.00%)	1 / 9 (11.11%)
occurrences (all)	2	0	1
Pain			
subjects affected / exposed	1 / 12 (8.33%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Pyrexia			

subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 11 (0.00%) 0	1 / 9 (11.11%) 1
Respiratory, thoracic and mediastinal disorders			
Productive cough			
subjects affected / exposed	0 / 12 (0.00%)	1 / 11 (9.09%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Oropharyngeal pain			
subjects affected / exposed	1 / 12 (8.33%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Nasal congestion			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Epistaxis			
subjects affected / exposed	1 / 12 (8.33%)	1 / 11 (9.09%)	0 / 9 (0.00%)
occurrences (all)	1	1	0
Dry throat			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Cough			
subjects affected / exposed	1 / 12 (8.33%)	1 / 11 (9.09%)	1 / 9 (11.11%)
occurrences (all)	1	1	1
Rhinalgia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Psychiatric disorders			
Daydreaming			
subjects affected / exposed	1 / 12 (8.33%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Apathy			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Insomnia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	2 / 9 (22.22%)
occurrences (all)	0	0	2
Irritability			

subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 11 (0.00%) 0	1 / 9 (11.11%) 1
Investigations Heart rate increased subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Injury, poisoning and procedural complications Procedural pain subjects affected / exposed occurrences (all)  Head injury subjects affected / exposed occurrences (all)  Fall subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0  0 / 12 (0.00%) 0  0 / 12 (0.00%) 0	0 / 11 (0.00%) 0  0 / 11 (0.00%) 0  0 / 11 (0.00%) 0	0 / 9 (0.00%) 0  0 / 9 (0.00%) 0  0 / 9 (0.00%) 0
Cardiac disorders Palpitations subjects affected / exposed occurrences (all)  Tachycardia subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0  0 / 12 (0.00%) 0	0 / 11 (0.00%) 0  0 / 11 (0.00%) 0	0 / 9 (0.00%) 0  1 / 9 (11.11%) 1
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)  Headache subjects affected / exposed occurrences (all)	3 / 12 (25.00%) 3  5 / 12 (41.67%) 11	1 / 11 (9.09%) 1  1 / 11 (9.09%) 2	1 / 9 (11.11%) 1  1 / 9 (11.11%) 1
Eye disorders Vision blurred subjects affected / exposed occurrences (all)  Visual impairment	1 / 12 (8.33%) 1	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0

subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 11 (9.09%) 1	0 / 9 (0.00%) 0
Gastrointestinal disorders			
Breath odour			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	1 / 12 (8.33%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Abdominal pain lower			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	2 / 12 (16.67%)	1 / 11 (9.09%)	0 / 9 (0.00%)
occurrences (all)	5	1	0
Abdominal distension			
subjects affected / exposed	1 / 12 (8.33%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Abdominal discomfort			
subjects affected / exposed	2 / 12 (16.67%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Constipation			
subjects affected / exposed	3 / 12 (25.00%)	0 / 11 (0.00%)	2 / 9 (22.22%)
occurrences (all)	3	0	2
Vomiting			
subjects affected / exposed	5 / 12 (41.67%)	0 / 11 (0.00%)	1 / 9 (11.11%)
occurrences (all)	8	0	3
Nausea			
subjects affected / exposed	8 / 12 (66.67%)	0 / 11 (0.00%)	5 / 9 (55.56%)
occurrences (all)	11	0	7
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 12 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	6 / 12 (50.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	10	0	0



Dry mouth subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Diarrhoea subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	1 / 11 (9.09%) 1	1 / 9 (11.11%) 2
Skin and subcutaneous tissue disorders Hyperhidrosis subjects affected / exposed occurrences (all)	2 / 12 (16.67%) 2	0 / 11 (0.00%) 0	1 / 9 (11.11%) 1
Renal and urinary disorders Pollakiuria subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	2 / 11 (18.18%) 2	0 / 9 (0.00%) 0
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 11 (0.00%) 0	1 / 9 (11.11%) 1
Torticollis subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Musculoskeletal pain subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Infections and infestations Nasopharyngitis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 11 (0.00%) 0	1 / 9 (11.11%) 1
Otitis media acute subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Pneumonia subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 11 (0.00%) 0	1 / 9 (11.11%) 1
Viral upper respiratory tract infection			

subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Metabolism and nutrition disorders			
Food craving			
subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Decreased appetite			
subjects affected / exposed occurrences (all)	3 / 12 (25.00%) 3	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0

<b>Non-serious adverse events</b>	Placebo (Part A)	Liraglutide (Part B)	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	7 / 9 (77.78%)	8 / 10 (80.00%)	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 2	
Chills			
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 1	
Fatigue			
subjects affected / exposed occurrences (all)	2 / 9 (22.22%) 2	1 / 10 (10.00%) 1	
Early satiety			
subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 10 (0.00%) 0	
Feeling cold			
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Injection site erythema			
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Injection site haematoma			
subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 10 (0.00%) 0	
Injection site rash			

subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Malaise subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 3	0 / 10 (0.00%) 0	
Pain subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Pyrexia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Respiratory, thoracic and mediastinal disorders Productive cough subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Oropharyngeal pain subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Nasal congestion subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 10 (0.00%) 0	
Epistaxis subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Dry throat subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Cough subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Rhinalgia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Psychiatric disorders			

Daydreaming subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Apathy subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Insomnia subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 10 (0.00%) 0	
Irritability subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 10 (0.00%) 0	
Investigations Heart rate increased subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 1	
Injury, poisoning and procedural complications Procedural pain subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 1	
Head injury subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 1	
Fall subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 10 (0.00%) 0	
Cardiac disorders Palpitations subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 2	
Tachycardia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Nervous system disorders Dizziness			

subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	2 / 10 (20.00%) 2	
Headache subjects affected / exposed occurrences (all)	3 / 9 (33.33%) 3	1 / 10 (10.00%) 3	
Eye disorders Vision blurred subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Visual impairment subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Gastrointestinal disorders Breath odour subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 1	
Abdominal pain upper subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Abdominal pain lower subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 1	
Abdominal pain subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Abdominal distension subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Abdominal discomfort subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Constipation subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	2 / 10 (20.00%) 2	
Vomiting			

subjects affected / exposed	1 / 9 (11.11%)	1 / 10 (10.00%)	
occurrences (all)	1	1	
Nausea			
subjects affected / exposed	2 / 9 (22.22%)	1 / 10 (10.00%)	
occurrences (all)	4	3	
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 9 (0.00%)	2 / 10 (20.00%)	
occurrences (all)	0	3	
Dyspepsia			
subjects affected / exposed	2 / 9 (22.22%)	1 / 10 (10.00%)	
occurrences (all)	3	2	
Dry mouth			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Diarrhoea			
subjects affected / exposed	2 / 9 (22.22%)	0 / 10 (0.00%)	
occurrences (all)	4	0	
Skin and subcutaneous tissue disorders			
Hyperhidrosis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Renal and urinary disorders			
Pollakiuria			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Torticollis			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences (all)	0	0	
Musculoskeletal pain			
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Infections and infestations			

Nasopharyngitis subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Otitis media acute subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Pneumonia subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 10 (0.00%) 0	
Metabolism and nutrition disorders			
Food craving subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 10 (0.00%) 0	
Decreased appetite subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	2 / 10 (20.00%) 2	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported